X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association and the proud father of his poodle-beagle mix Molly.

Recent Posts

ICYMI: New era of medicine initiative kicks off in Boston

By Andrew Powaleny  |    February 22, 2017
It’s no secret that Boston, Massachusetts is home to many of the most groundbreaking advancements in medical discovery. That’s why yesterday, PhRMA sponsored its first national health care...   Read More

Watch: Biomarkers in drug development with Dr. Bernie Zeiher

By Andrew Powaleny  |    February 14, 2017
Biomarkers are powerful tools which are used by medical professionals in many ways, including in the diagnosis of disease, monitoring how a disease is progressing and, if a treatment is given, how...   Read More

The 20-year journey yielding a new weapon against cancer

By Andrew Powaleny  |    January 10, 2017
Developing new medicines is a long, complex process. On average, it takes at least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient’s...   Read More

3 things to know about 2016 drug approvals

By Andrew Powaleny  |    January 6, 2017
In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need. These...   Read More

Video: Translating science into new medicines

By Andrew Powaleny  |    December 12, 2016
Researchers and scientists at America’s biopharmaceutical companies and around the globe work every day to translate science into new treatments and cures to allow patients to live longer,...   Read More

World AIDS Day 2016: A decade of scientific innovation

By Andrew Powaleny  |    December 1, 2016
On World AIDS Day, we are reminded of the significant advances that have been made – many of which occurred over the past decade – to help transform HIV/AIDS from a once acutely fatal epidemic to...   Read More

Building on the promise of personalized medicine

By Andrew Powaleny  |    November 16, 2016
PhRMA’s member companies are on the leading edge of personalized medicine development– an area that is transforming health care, improving patient outcomes and creating health system efficiencies....   Read More

ICYMI: More than 60 PhRMA company scientists visit Capitol Hill

By Andrew Powaleny  |    September 30, 2016
Last week, PhRMA brought more than 60 member company researchers and scientists to Capitol Hill for a biopharmaceutical researcher fly-in. The fly-in highlighted the important science that’s...   Read More

Harnessing the power of real-world evidence to benefit patients through PDUFA VI

By Andrew Powaleny  |    September 6, 2016
America’s biopharmaceutical researchers are in a golden era of medical research, discovery and development for patients. Rapid advances in technology and science have enhanced our ability to use...   Read More

How modernizing FDA regulations can benefit patients, providers and payers

By Andrew Powaleny  |    September 1, 2016
Yesterday, the U.S. Food and Drug Administration (FDA) announced a two-day hearing slated for November 9 and 10, seeking public input as the agency works to review and potentially revise its...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates